ICU Medical, Inc. $ICUI Shares Purchased by Fox Run Management L.L.C.

Fox Run Management L.L.C. raised its stake in ICU Medical, Inc. (NASDAQ:ICUI) by 129.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,588 shares of the medical instruments supplier’s stock after purchasing an additional 4,842 shares during the period. Fox Run Management L.L.C.’s holdings in ICU Medical were worth $1,030,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of ICUI. River Road Asset Management LLC grew its position in shares of ICU Medical by 207.0% in the 2nd quarter. River Road Asset Management LLC now owns 651,492 shares of the medical instruments supplier’s stock valued at $83,658,000 after buying an additional 439,263 shares during the last quarter. Norges Bank acquired a new position in ICU Medical in the second quarter valued at $36,633,000. Federated Hermes Inc. grew its holdings in shares of ICU Medical by 56.5% during the third quarter. Federated Hermes Inc. now owns 290,292 shares of the medical instruments supplier’s stock worth $34,823,000 after purchasing an additional 104,798 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of ICU Medical by 75.1% during the second quarter. The Manufacturers Life Insurance Company now owns 228,909 shares of the medical instruments supplier’s stock worth $30,250,000 after purchasing an additional 98,147 shares during the last quarter. Finally, Quantinno Capital Management LP increased its position in shares of ICU Medical by 129.9% during the second quarter. Quantinno Capital Management LP now owns 135,142 shares of the medical instruments supplier’s stock worth $17,859,000 after purchasing an additional 76,352 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Trading Up 1.7%

Shares of ICUI stock opened at $155.12 on Thursday. The company has a market capitalization of $3.83 billion, a P/E ratio of 7,759.88, a price-to-earnings-growth ratio of 2.16 and a beta of 0.79. The company has a current ratio of 2.39, a quick ratio of 1.15 and a debt-to-equity ratio of 0.60. The business’s 50 day moving average is $149.75 and its two-hundred day moving average is $136.55. ICU Medical, Inc. has a twelve month low of $107.00 and a twelve month high of $160.29.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Thursday, February 19th. The medical instruments supplier reported $1.91 earnings per share for the quarter, topping the consensus estimate of $1.68 by $0.23. ICU Medical had a return on equity of 7.33% and a net margin of 0.03%.The firm had revenue of $535.94 million during the quarter, compared to the consensus estimate of $541.20 million. During the same period last year, the company earned $2.11 earnings per share. The company’s revenue for the quarter was down 14.1% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Equities analysts forecast that ICU Medical, Inc. will post 4.11 EPS for the current year.

Wall Street Analysts Forecast Growth

ICUI has been the subject of a number of research analyst reports. Piper Sandler upped their target price on ICU Medical from $172.00 to $178.00 and gave the company an “overweight” rating in a research report on Friday, February 20th. Wall Street Zen upgraded ICU Medical from a “hold” rating to a “buy” rating in a research note on Sunday, February 15th. KeyCorp increased their price objective on ICU Medical from $175.00 to $180.00 and gave the company an “overweight” rating in a report on Friday, February 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ICU Medical in a report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, ICU Medical presently has a consensus rating of “Moderate Buy” and an average target price of $179.33.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.